Active Studies: Completed Recruitment


Full Study Title: AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study

Principal Investigators: Leslie Skeith, Marc Rodger

Funding: CanVECTOR Pilot, LEO (Leo Pharma)

Design: Open-label pilot RCT of antepartum prophylaxis with LMWH and ASA versus ASA alone in women with confirmed antiphospholipid syndrome (APS) and a history of past pregnancy loss

For more informationNCT03100123


Full Study Title: Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

Principal Investigator: Phil Wells

Funding: HSF (Heart and Stroke Foundation of Canada)

Design: Cohort study of VTE (Venous Thromboembolism) patients on anticoagulants to derive a decision rule for bleeding

For more information: NCT00788736

Published Abstract: ISTH 2017 - Research and Practice in Thrombosis and Haemostasis: Bleed Risk 


02. COBRRA Pilot

Full Study Title: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban

Principal Investigator: Lana Castellucci

Funding: CanVECTOR Pilot

Design: Open-label pilot RCT (randomized clinical trial) comparing bleeding risk with rivaroxaban versus apixaban

For more information: NCT02559856


Full Study Title: Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

Principal Investigators: Lana Castellucci, Thomas Ortel, David Garcia

Patient Partner: Ryan O'Connell

Funding: PCORI (Patient-Centered Outcomes Research Institute)

Design: Pragmatic open-label RCT (randomized clinical trial) comparing the safety and efficacy of rivaroxaban, apixaban and warfarin for the long-term treatment of unprovoked VTE (venous thromboembolism).

For more information: NCT03196349


Full Study Title: Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran

Principal Investigators: Sam Schulman, Susan Kahn

Funding: BI (Boehringer Ingelheim Canada)

Design: Cohort of patients enrolled in RECOVER I and II to assess the prevalence of PTS (post-thrombotic syndrome) using the recently developed patient self-reported Villalta (PRV) Scale

For more information: NCT03050138


Full Study Title: Perioperative Anticoagulant Use for Surgery Evaluation Study

Principal Investigator: Jim Douketis

Funding: CIHR (Canadian Institutes of Health Research), HSF (Heart and Stroke Foundation of Canada)

Design: Prospective cohort study of patients with atrial fibrillation on new oral anticoagulants requiring interruption for elective surgery/procedure; looking to develop a safer perioperative protocol

For more information: NCT02228798


06. PERIOP 2

Full Study Title: A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin

Principal Investigator: Michael Kovacs

Funding: CIHR (Canadian Institutes of Health Research), Pfizer

Design: Double-blind RCT (randomized clinical trial) of post-procedure bridging with LMWH (low-molecular-weight heparin) versus placebo for patients on long-term warfarin who require temporary interruption of warfarin

For more information: NCT00432796



Full Study Title: Tumor-educated Platelets in Venous Thromboembolism

Principal Investigators: Noemie Kraaijpoel, Marc Carrier

Funding: CanVECTOR Pilot

Design: Pilot prospective cohort study assessing the diagnostic accuracy of platelet mRNA profiling for occult cancer in the setting of VTE (venous thromboembolism) -  (primary outcome of the pilot is the recruitment rate)

For more informationNCT02739867


Full Study Title: Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis

Principal Investigators: Gregoire Le Gal

Funding: HSF (Heart and Stroke Foundation of Canada)

Design: Prospective cohort of patients with a history of thrombosis and new symptoms of VTE (venous thromboembolism); evaluating the performance of current clinical decision rules with this population

For more information: NCT02297373



Full Study Title: Rivaroxaban Anticoagulation for Superficial Vein Thrombosis

Principal Investigator: Clive Kearon

Funding: Bayer

Design: Double-blind RCT (randomized clinical trial) of rivaroxaban versus placebo for treatment of superficial vein thrombosis

For more information: NCT02123524

11. SAVER Pilot

Full Study Title: StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study

Principal Investigator: Marc Rodger

Patient Partners: Rob Adriaanse, Ryan O'Connell

Funding: CIHR (Canadian Institutes of Health Research)

Design: Open-label pilot RCT (randomized clinical trial) of rosuvastatin to prevent recurrent VTE (venous thromboembolism) and reduce PTS (post-thrombotic syndrome) in patients with VTE (venous thromboembolism)

For more information: NCT02679664


Full Study Title: Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots

Principal Investigator: Vicky Tagalakis

Funding: Sanofi

Design: Pilot management cohort study involving cancer patients with DVT (deep vein thrombosis) or PE (pulmonary embolism); step down to prophylactic doses of enoxaparin after 3-6 months of full-dose treatment

For more information:NCT02752607